Casey Anthony Sentence - July 7, 2011 - 07/07/2011

Judge Perry sentenced Casey Anthony today, July 7, 2011. Casey Anthony was sentenced to the maximum of 1 year of jail time and a $1000 fine for each of 4 consecutive accounts of providing false information to law enforcement officers. However, due to jail time already served and good behavior, she may be released within the next 2-3 months. Judge Perry denied the defense's motion to combine all 4 accounts into 1 account. Judge Perry may also decide to fine Casey Anthony for the money and time spent by law enforcement officers who were searching for a child, based on Casey Anthony's lies. Casey Anthony and her team have not yet decided if they will appeal the sentence, they have 30 days to do so.

Casey Anthony Sentencing Time - July 7, 2011

After being charged NOT GUILTY on the accounts of Murder in the 1st Degree, Manslaughter, and aggravated child abuse of her daughter Caylee Anthony, Casey Anthony will be sentenced on 4 accounts of providing false information to law enforcement officers (i.e. lying to police officers.

Her sentencing will take place on July 7, 2011 at 9 AM eastern time.

She faces up to 4 years in prison, minus the 2.5 years already served.

Casey Anthony Sentencing Date - July 7, 2011

After being charged NOT GUILTY on the accounts of Murder in the 1st Degree, Manslaughter, and aggravated child abuse of her daughter Caylee Anthony, Casey Anthony will be sentenced on 4 accounts of providing false information to law enforcement officers (i.e. lying to police officers.

Her sentencing will take place on July 7, 2011 at 9 AM eastern time.

She faces up to 4 years in prison, minus the 2.5 years already served.

Casey Anthony: Verdict - Not Guilty: July 5, 2011

Today, July 5, 2011, the judicial court system failed Caylee Marie Anthony by finding Casey Marie Anthony not guilty for 1st Degree Murder, Manslaughter and Aggravated child abuse. I am personally appalled and disappointed that our court system failed this young child and leaves a murderer out on the streets.

Stock Market 6-23-11 June 23, 2011, DOW Jones

The stock market is in the red today with the DOW jones dropping over 210 points at one point. Aside from the Greece debt crisis, initial jobless claims were once again disappointing. The stock market also took a tumble due to the Department of Energy releasing oil from the strategic petroleum reserves.

One positive in the stock market today was the housing data. New home sales for May, 2011 were 319,000 which is better than the 290,000 forecast.

Stock market events 6-24-11, June 24, 2011:

Economic Data - GDP Q1 estimate 8:30 AM and durable orders for May, 2011 due out at 8:30 AM.

University of Michigan Cancer Center receives Millions for Cancer Research

The University of Michigan Comprehensive Cancer Center has received a five-year $10.7 million grant from the National Cancer Institute to study colorectal and pancreatic cancer.

The Specialized Program in Research Excellence or SPORE, grant in gastrointestinal cancers brings together basic and clinical researchers to test new approaches for cancer prevention, early detection, diagnosis and treatment.

"This grant represents a major effort to bridge the basic science to the clinic. You have to have very good science, but it also has to translate: How are we going to use this information to help patients? The depth of expertise at the University of Michigan allows us to pursue this work," says Dean Brenner, MD principal investigator of the new grant and a professor of internal medicine and pharmacology at the U-M Medical School and the Ann Arbor VA Healthcare System.

Researchers from nine different departments from the U-M Medical School and School of Public Health will collaborate on the grant.

The Gastrointestinal SPORE grant is centered on four major projects, all of which will be tested in both laboratory research and clinical trials:

1. Preventing colorectal cancer. Researchers will study whether substituting omega-3 fatty acids for omega-6 fatty acids could help prevent colorectal cancer. Omega-3 fatty acids are found in fish and are believed to improve heart health.

2. Early detection of pancreatic cancer. Researchers will look for markers found in blood and plasma that are associated with pancreatic cancer. By using proteomics technology, researchers will analyze the changes in proteins in people with pancreatic cancer, non-cancerous pancreatic conditions and healthy pancreases. They hope to identify a marker or panel of markers that could be used to detect pancreatic cancer before it spreads to the rest of the body.

3. Improving pancreatic cancer treatment. Researchers will look at whether blocking a certain protein could make pancreas tumors more sensitive to chemotherapy and radiation therapy. By doing this, researchers hope to improve the effectiveness of current treatments.

4. Developing new pancreatic cancer treatments. Most pancreatic cancers express a gene called ATDC. Researchers will look at new therapies designed to target ATDC as a way of treating pancreatic cancer.

The grant also allows for training of young cancer researchers to encourage the next generation of scientists.

Colorectal cancer statistics: 142,570 Americans will be diagnosed with colorectal cancer this year and 51,370 will die from the disease.

Pancreatic cancer statistics: 43,140 Americans will be diagnosed with pancreatic cancer this year, and 36,800 will die from the disease. Pancreatic cancer is one of the most deadly cancer types, with more than 70% of patients dying within six months of diagnosis.

McKesson Corp. (MCK) acquires US Oncology for $2.16 Billion

By Andrea: http://nursingoncologyjob.com

McKesson Corporation (MCK), a leading healthcare services and information technology company, and US Oncology, a leading integrated oncology company, recently announced that the two companies have signed a definitive agreement under which McKesson will purchase all outstanding shares of US Oncology for cash. The total transaction, including the assumption of US Oncology's outstanding debt, is valued at approximately $2.16 billion. The combined organization will focus on providing a comprehensive offering of solutions for the oncology industry, one of the fastest-growing segments in healthcare.

The parties are targeting a closing by the end of McKesson's third fiscal quarter, ending December 31, 2010, subject to customary conditions, including all necessary regulatory clearances. Excluding transaction and integration costs, the acquisition is expected to be neutral to McKesson's diluted earnings per share in its current fiscal year, and modestly accretive beginning in McKesson's fiscal year 2012. In connection with the acquisition, it is anticipated that substantially all of US Oncology's debt will be repaid or refinanced, including the Senior Floating Rate PIK Toggle Notes due 2012 issued by US Oncology Holdings, Inc., and the 9.125% Senior Secured Notes due 2017 and 10.75% Senior Subordinated Notes due 2014, both issued by US Oncology, Inc.

The unified organization will bring together the collective capabilities of McKesson and US Oncology to provide oncology customers access to:

• Leading evidence-based medicine offerings that drive continued improvements in clinical outcomes and enable value-based reimbursement;
• Expanded clinical expertise, clinical research and personalized medicine offerings;
• Integrated, efficiency-enabling healthcare information technology, including the iKnowMed(TM) and Lynx^(R) technology platforms, facilitating outcomes measurement, reporting, and advanced product and inventory management;
• Innovative practice-management solutions and consultative capabilities that allow independent community specialists to thrive in a changing healthcare environment; and
• Superior distribution capabilities and supply-chain expertise.

These solutions will help community oncologists improve the care experience for patients and drive business and clinical innovations that address the increasing demand for high-quality, cost-effective, personalized cancer care.

"McKesson is committed to improving the health and vitality of our customers, with the ultimate goal of improving the health of patients," said John H. Hammergren, chairman and chief executive officer, McKesson. "The combination of US Oncology and McKesson will enhance our ability to achieve these goals in one of the most important segments in healthcare. Community oncology practices need strategic support that offers not only technology and distribution solutions, but also value-added clinical and reimbursement management services that enable them to provide the highest-quality, most efficient care to their patients. With this acquisition, McKesson will offer a compelling suite of services and solutions to community oncologists and other partners in the rapidly evolving specialty business."

The combined McKesson Specialty Care Solutions business will be led by Bruce Broussard, chairman and chief executive officer of US Oncology, and will be headquartered in The Woodlands, Texas, with continuing operations in the San Francisco Bay Area and other locations throughout the country. Broussard will report to Paul Julian, executive vice president and group president, McKesson Corporation. McKesson will continue to operate the United Network of US Oncology, including US Oncology's Comprehensive Strategic Alliance offering, US Oncology Research and other services under the US Oncology brand name.

Strategic Acquisition Creates Broader, Deeper Oncology Offering

The unified company will deliver a best-in-class oncology program, clinical tools, guidelines and care pathways that will create a leader in evidence-based medicine backed by a deep team of clinical experts. With approximately 3,000 total physician customers, the new organization's expanded breadth will accelerate investments in integrated systems, process excellence, and clinical programs that will help drive productivity, efficient care delivery, and the best possible care experience for patients.

"With the healthcare marketplace moving rapidly toward reimbursement based on quality and cost-effectiveness, our physician customers need access to deep clinical, operational and information technology capabilities to create integrated networks that continually enhance the quality of care in a cost-efficient manner," said Bruce Broussard. "In joining McKesson, we are building the scale and expertise necessary to empower our customer base to shape the future of healthcare."

"The addition of US Oncology's physician-centric business model and clinical expertise to the McKesson portfolio advances our strategy and significantly strengthens our offering for community oncology and other partners in the specialty segment," said Paul Julian. "McKesson and US Oncology's businesses are highly complementary, providing our collective customers access to more services and solutions that will enhance their ability to deliver advanced cancer care."

Unified Organization Creates More Choices for Community Oncology

Together, McKesson and US Oncology will provide oncology practices with a robust suite of practice-support options and services, which can be tailored to meet each customer's specific needs. US Oncology's existing Comprehensive Strategic Alliance (CSA) practice-management offering and core services will remain intact, while the combined organization will offer a broad array of a la carte technology, practice-management, reimbursement and clinical services to the community oncology segment. US Oncology does not employ the physicians or own the practices affiliated with the company, and all customers will retain the flexibility to select the business-relationship model that best suits their individual needs.

"This strategic acquisition is a logical next step in our commitment to ensure the continued vitality of community oncology, while creating value for our shareholders," concluded Hammergren. "We look forward to welcoming US Oncology's innovative, experienced employees to McKesson and to working together with our customers to create better health for our customers and the patients they serve."

About US Oncology

US Oncology, Inc. is the nation's leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with more than 1,300 community-based oncologists, and works with patients, hospitals, payors and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience.

About McKesson

McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes, and improving the quality and safety of patient care. Over the course of its 177-year history, McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients.

For more cancer updates, visit: http://astopnews.blogspot.com

For more stock updates, visit: http://daytradingstockblog.blogspot.com